Department of Surgery, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Department of Medical Oncology, Affiliated Tumor Hospital of Nantong University & Nantong Tumor Hospital, Nantong, 226361, China.
Mol Cancer. 2024 Aug 9;23(1):163. doi: 10.1186/s12943-024-02070-3.
This study details a case of a patient with advanced lung adenocarcinoma harboring an exon 19 deletion in the EGFR gene.
A 46-year-old female patient was diagnosed with stage IVb left lung adenocarcinoma, with multiple bone and lymph node metastases. Following the identification of tumor-specific antigen peptides, the patient received a combination treatment of immunotherapy (TSA-DC-CTL) and oral osimertinib. Peripheral blood circulating immune cells and circulating tumor cells (CTCs) were monitored before and after treatment. PET-CT and CT scans were used to assess the tumor response to treatment.
A significant increase in total lymphocyte percentage and decrease in the number of CTCs in the patient was observed. Imaging studies showed a notable reduction in tumor metastases.
This report demonstrates the safety and efficacy of TSA-DC-CTL cell immunotherapy combined with osimertinib in the treatment of a patient with advanced lung adenocarcinoma with an EGFR exon 19 deletions. This study describes a promising new treatment option for patients with advanced lung cancer with EGFR mutations.
本研究详细介绍了一例携带 EGFR 基因外显子 19 缺失的晚期肺腺癌患者。
一名 46 岁女性患者被诊断为 IVB 期左肺腺癌，伴多处骨和淋巴结转移。在鉴定肿瘤特异性抗原肽后，患者接受了免疫治疗（TSA-DC-CTL）联合口服奥希替尼的联合治疗。治疗前后监测外周血循环免疫细胞和循环肿瘤细胞（CTC）。采用 PET-CT 和 CT 扫描评估肿瘤对治疗的反应。
患者的总淋巴细胞百分比显著增加，CTC 数量减少。影像学研究显示肿瘤转移明显减少。
本报告证明了 TSA-DC-CTL 细胞免疫疗法联合奥希替尼治疗携带 EGFR 外显子 19 缺失的晚期肺腺癌的安全性和有效性。本研究为携带 EGFR 突变的晚期肺癌患者提供了一种有前途的新治疗选择。
